With his monstrous but lovable features, green skin, and pro wrestler's build, the cartoon ogre Shrek remains instantly ...

“The acceptance of our NDA for paltusotine in acromegaly was a key achievement ... Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational ...

We anticipate filing the EMA for acromegaly shortly ... a TSH antagonist for Graves hyperthyroidism and thyroid eye disease and an SST3 agonist for autosomal dominant polycystic kidney disease ...

Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational ...

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.